Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:388 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 388(2023), 9 vom: 02. März, Seite 857-859 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alves, Katia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2SCD8Q63PF |
|---|
| Anmerkungen: |
Date Completed 03.03.2023 Date Revised 03.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMc2215509 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352449543 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352449543 | ||
| 003 | DE-627 | ||
| 005 | 20231226053743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMc2215509 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352449543 | ||
| 035 | |a (NLM)36734884 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alves, Katia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.03.2023 | ||
| 500 | |a Date Revised 03.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a NVX-CoV2373 adjuvated lipid nanoparticle |2 NLM | |
| 650 | 7 | |a 2SCD8Q63PF |2 NLM | |
| 700 | 1 | |a Plested, Joyce S |e verfasserin |4 aut | |
| 700 | 1 | |a Galbiati, Shirley |e verfasserin |4 aut | |
| 700 | 1 | |a Chau, Gordon |e verfasserin |4 aut | |
| 700 | 1 | |a Cloney-Clark, Shane |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Mingzhu |e verfasserin |4 aut | |
| 700 | 1 | |a Kalkeri, Raj |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Nita |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Kathy |e verfasserin |4 aut | |
| 700 | 1 | |a Marcheschi, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Pfeiffer, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a McFall, Heather |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Gale |e verfasserin |4 aut | |
| 700 | 1 | |a Glenn, Gregory M |e verfasserin |4 aut | |
| 700 | 1 | |a Dubovsky, Filip |e verfasserin |4 aut | |
| 700 | 1 | |a Mallory, Raburn M |e verfasserin |4 aut | |
| 700 | 0 | |a Novavax 2019nCoV-101 Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 388(2023), 9 vom: 02. März, Seite 857-859 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:388 |g year:2023 |g number:9 |g day:02 |g month:03 |g pages:857-859 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMc2215509 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 388 |j 2023 |e 9 |b 02 |c 03 |h 857-859 | ||